UNITE4TB

🌍 Today, 24 March, is World TB Day – a time to unite, raise awareness, and accelerate progress towards ending tuberculosis (TB). UNITE4TB is committed to transforming TB treatment through cutting-edge research and global collaboration. By advancing the development of safer, shorter, and more effective TB regimens, we are working towards a future where TB is no longer a public health threat. This World TB Day, we reaffirm our dedication to innovation, partnership, and the urgent need for better TB treatments. #WorldTBDay #YesWeCanEndTB #CommitInvestDeliver #TBResearch #GlobalHealth #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator In partnership with: Lygature, Radboudumc, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, Oxford University Clinical Research Unit, Research Center Borstel, Lancaster University, UCL, MRC Clinical Trials Unit at UCL, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, University of Hamburg, University of California, San Francisco, TB Alliance, FIND, Università degli Studi di Milano, University of St Andrews, Uppsala University, European Respiratory Society, TBnet, GSK, Johnson & Johnson, Ludwig-Maximilians-Universität München, LMU Klinikum München, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research. With thanks to Charles Wells of the Gates Medical Research Institute, Kelly Dooley of the Vanderbilt University Medical Center, and Phumeze Tisile, TB survivor and TB Proof / Global Coalition of TB Advocates (GCTA) Board Member.

📢 UNITE4TB is pleased to announce that the ENABLE study is the latest trial to be added to its growing clinical trial program, marking another step forward in the fight against tuberculosis (TB) 💪 By integrating ENABLE, we are strengthening our commitment to accelerating the development of safer, more effective TB treatments. The study is being conducted under the collaboration between BioVersys AG and GSK, with clinical trial implementation led by TASK. 🔗 Read more 👉 https://lnkd.in/ewM2unXS #UNITE4TB #TBResearch #ClinicalTrials #GlobalHealth #YesWeCanEndTB #CommitInvestDeliver #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator

⌛ Call to apply for the UNITE4TB Young Investigators Group closes on February 14. If you're an early career scientist with a background in the field of #tuberculosis research and you would like to actively collaborate with experts in the field, make sure to apply 👇 https://lnkd.in/eEcCJ4h7 #UNITE4TB #tuberculosis #EndTB #globalhealth #youngscientists #engagement #publicprivatepartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). ISPUP | Instituto de Saúde Pública da Universidade do Porto European Respiratory Society TBnet

Join the UNITE4TB Young Investigators Group. Apply before 14 February👉 https://lnkd.in/eEcCJ4h7 #UNITE4TB #Tuberculosis #EndTB #GlobalHealth #YoungScientists #publicprivatepartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)) AMR Accelerator ISPUP | Instituto de Saúde Pública da Universidade do Porto European Respiratory Society TBnet

📢 Join the UNITE4TB Young Investigators Group   🤝 To connect with early career scientists and develop outreach activities, UNITE4TB has established a Young Investigators Group (YIG) for which we are currently seeking new members. To be considered, applicants should be no older than 40 and have a background in the field of TB research.   Interested? Make sure to apply before February 14👇 https://lnkd.in/eEcCJ4h7   #UNITE4TB #tuberculosis #EndTB, #globalhealth, #youngscientists #engagement #publicprivatepartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)).   ISPUP | Instituto de Saúde Pública da Universidade do Porto European Respiratory Society TBnet

As the year draws to a close, we're happy to share the latest edition of the UNITE4TB Newsletter, packed full of updates and insights on our ongoing efforts to accelerate the development of new treatment regimens for tuberculosis (TB). In this issue: 🔹 UNITE4TB project lead, Derek Sloan, reflects on the year that has been and how the work of the Consortium is reshaping the global TB landscape 🔹 We provide an update on the status of the UNITE4TB clinical trial program 🔹 We look back at our collaboration with PAN-TB at this year's Union Conference 🔹 We proudly share our joint call for sustained investment in TB and antibiotic research These stories and more! 🔗👉 https://lnkd.in/ghPw7zhB Subscribe to our newsletter for the latest news and updates (see link in comments) #UNITE4TB #EndTB #GlobalHealth #Newsletter #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator. In partnership with: Radboudumc, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, Oxford University Clinical Research Unit, Research Center Borstel, Lygature, Lancaster University, UCL, MRC Clinical Trials Unit at UCL, UCL, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, University of Hamburg, University of California, San Francisco, TB Alliance, FIND, Università degli Studi di Milano, Centre Multidisciplinary Research in Health Science , School of Medicine, University of St Andrews, University of St Andrews, Farmaceutiska fakulteten • Uppsala universitet, Uppsala University, European Respiratory Society, TBnet, GSK, Johnson & Johnson, Ludwig-Maximilians-Universität München, LMU Klinikum München, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research

🌍 Collaborating to Transform TB Drug Development 🤝 UNITE4TB proudly joined forces with the PAN-TB Collaboration at this year’s Union Conference on Lung Health in Bali to highlight the critical role of collaboration in driving innovation for TB drug development. The session featured insights from developers, policymakers, and community representatives, emphasizing the challenges and opportunities in the new regimen development process. Read more 👉 https://lnkd.in/evz2wRp7 #UNITE4TB #PANTB #UnionConf2024 #tuberculosis #EndTB #PublicPrivatePartnership Innovative Health Initiative (IHI), AMR Accelerator, Jodie Schildkraut, Barros David, Paul Sommerfeld, Maria Tarcela Gler, Fuad Mirzayev, David Holtzman, Bill & Melinda Gates Medical Research Institute

📢Have you registered yet for the fourth and final #UNITE4TB #webinar of 2024? The webinar will feature a discussion on intersecting the vulnerabilities of TB in migrants: prevention and care strategies Speaker: Dr Jessica Potter (London, United Kingdom) Date and time: 28 November, 13:00–14:00 CET Find out more and register 👉 https://lnkd.in/e569YrMg ISPUP | Instituto de Saúde Pública da Universidade do Porto, European Respiratory Society, Innovative Health Initiative (IHI), AMR Accelerator

PARADIGM4TB Update As part of the UNITE4TB Phase 2B/C clinical trial program, the PARADIGM4TB trial is setting new standards in TB research. In a recent interview, Dr. Ilaria Motta from the MRC Clinical Trials Unit at UCL shared insights into the trial's progress, challenges, and future milestones. 💡 Key Highlights:  - PARADIGM4TB is a platform trial evaluating innovative combinations of TB treatments, aiming to shorten development timelines. - Since January, 100 participants have been enrolled across sites in South Africa, Tanzania, and Uganda, with plans to expand to Asia, Europe, and South America in 2025. - The trial represents a collaborative effort to not only develop novel therapies but also to redefine how TB trials are conducted. Read the full interview 👉 https://lnkd.in/eXa6gz7f #UNITE4TB #ClinicalTrials #PARADIGM4TB #GlobalHealth #PublicPrivatePartership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI). AMR Accelerator UCL

📢PAN-TB Collaboration & UNITE4TB at the Union Conference 2024! What does it take to advance a TB drug through complex trials and into public health programs? Hear directly from developers, policymakers, and the community perspective on navigating global trial challenges, including non-clinical requirements for underserved populations and community support for trial assessments. Our Satellite Session at the Union Conference in Bali on 14 November will also showcase how partnerships like the #PANTB Collaboration and #UNITE4TB streamline drug regimen development through collective work – along with an update from the PAN-TB Phase 2b/c trial. More info: http://bit.ly/3NF1C0A #UnionConf2024 #tuberculosis #innovation #EndTB #PublicPrivatePartnership Innovative Health Initiative (IHI), AMR Accelerator, Jodie Schildkraut, Barros David, Paul Sommerfeld, Maria Tarcela Gler, Fuad Mirzayev, David Holtzman